Daily Low-Dose Subcutaneous Interleukin-2 Added To Single- or Dual-Nucleoside Therapy in HIV Infection Does Not Protect Against CD4+ T-Cell Decline or Improve Other Indices of Immune Function: Results of a Randomized Controlled Clinical Trial (ACTG 248)

作者
Mary A. Vogler,Hedy Teppler,Rebecca Sue Gelman,Fred T. Valentine,Michael M. Lederman,Roger J. Pomerantz,Richard B. Pollard,Deborah Weng Cherng,Charles J. Gonzalez,Kathleen Squires,Ian Frank,Donna Mildvan,Laura F. Mahon,Barbara Schock
出处
期刊:Journal of Acquired Immune Deficiency Syndromes [Lippincott Williams & Wilkins]
卷期号:36 (1): 576-587 被引量:18
标识
DOI:10.1097/00126334-200405010-00005
摘要

CONTEXT: Approaches to preserve or enhance immune function in HIV-1 infection are needed. OBJECTIVES: To examine the ability of daily low-dose interleukin-2 (IL-2) in combination with antiretroviral therapy to preserve circulating CD4+ T-cell counts, the clinical safety and tolerability of this treatment, and safety with respect to changes in plasma HIV-1 RNA levels. DESIGN: Twenty-four-week, phase 2, multicenter, randomized, open-label trial conducted at 12 AIDS Clinical Trials Units between September 1995 and May 1997. PARTICIPANTS: A total of 115 HIV-infected persons with screening CD4+ T-cell counts between 300 and 700 cells/mm who were on stable single- or dual-nucleoside therapy for at least 2 months, 11% of whom were also on a protease inhibitor at study entry. INTERVENTIONS: Patients were randomly assigned to receive IL-2 at a dose of 1 million IU subcutaneously once daily plus continued anti-retroviral therapy (ART + IL-2, n = 57) vs. continued ART alone (ART alone, n = 58). IL-2 dose reductions were made for objective or subjective toxicities. All subjects randomly assigned to the IL-2 arm who interrupted ART were also required to discontinue IL-2 for the same period. MAIN OUTCOME MEASURES: The primary endpoint was a decrease in CD4 T-cell count from baseline; the safety analysis was based on change in plasma HIV RNA by bDNA; and clinical safety and tolerability were analyzed by standard clinical criteria. RESULTS: Of the patients with a baseline CD4 T-cell count recorded, 15 (27%) of 55 patients randomly assigned to ART alone had a drop of > or =25% in their CD4 T-cell count and 23 (41%) of 56 patients randomly assigned to ART + IL-2 had a drop of > or =25% in their CD4 T-cell count at some time over the 24 weeks of the study. This difference was not statistically significant. There was a statistically significant greater variance in CD4 T-cell counts in the IL-2-treated group. More patients in the IL-2 group had at least a 25% increase in CD4 T-cell counts over baseline (34 vs. 13%, P = 0.007). A comparison of grade 3 or worse toxicity showed no differences between the arms, but IL-2 was associated with significantly more grade 2 or worse general body symptoms, primarily discomfort and fatigue. There was no significant difference between the groups with regard to changes in plasma HIV RNA, lymphocyte proliferation, natural killer cell activity, skin test responses to recall antigens, or antibody responses to immunization. Plasma markers of immune activation all increased significantly in IL-2 recipients. CONCLUSIONS: In patients with baseline CD4 T-cell counts > or =300 cells/mm primarily treated with single- or dual-nucleoside ART, subcutaneously administered IL-2 at a dose of 1 million IU daily for up to 24 weeks had low toxicity but showed no consistent benefit in preventing decline in CD4 T-cell counts and minimal evidence of immunologic improvement vs. continued ART alone.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
景碧空完成签到 ,获得积分10
1秒前
wangbw发布了新的文献求助10
1秒前
2秒前
灿烂sunfly完成签到,获得积分10
2秒前
2秒前
Benthesikyme发布了新的文献求助10
3秒前
科研通AI2S的应助被我爱睡大觉采纳,获得30
3秒前
研友_VZG7GZ的应助被紧张的文博采纳,获得10
5秒前
周江阔发布了新的文献求助10
5秒前
5秒前
6秒前
多多发布了新的文献求助10
6秒前
思源的应助被追寻如萱采纳,获得10
6秒前
6秒前
Jello发布了新的文献求助10
7秒前
无极微光的应助被清绘采纳,获得20
7秒前
7秒前
KKZNB发布了新的文献求助10
7秒前
Orange的应助被和谐的雪瑶采纳,获得30
8秒前
逆流的鱼完成签到,获得积分10
9秒前
852的应助被tang采纳,获得10
9秒前
10秒前
molihuakai的应助被Benthesikyme采纳,获得10
10秒前
1st发布了新的文献求助10
10秒前
深情安青的应助被科研通管家采纳,获得10
11秒前
11秒前
Nicu发布了新的文献求助10
11秒前
Jun的应助被科研通管家采纳,获得20
11秒前
上官若男的应助被科研通管家采纳,获得10
11秒前
12秒前
CarryLJR的应助被湖工大保卫处采纳,获得10
12秒前
爆米花的应助被科研通管家采纳,获得10
12秒前
12秒前
小萌兽发布了新的文献求助50
12秒前
Orange的应助被科研通管家采纳,获得10
12秒前
ding的应助被科研通管家采纳,获得10
12秒前
syvshc的应助被nikola采纳,获得10
12秒前
CodeCraft的应助被科研通管家采纳,获得10
12秒前
12秒前
华仔的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593